John is the President of Valaria Technical Consultants, LLC where he serves as a Senior Advisor for funding and partnering on product development for therapeutics, vaccines and diagnostics. John has over 30 years of infectious disease research and development and scientific administration including 14 years serving as Scientific Review Officer, Program Officer and Technology Development Specialist at the National Institute of Allergy and Infectious Disease working with NIH’s intramural and extramural communities. He is experienced in other metabolic human diseases and bioinformatics and has over 32 years scientific, laboratory and project management. John obtained a B.S. in Biology from Rensselaer Polytechnic Institute and M.A. and Ph.D. in Microbiology and Immunology from the State University of New York at Buffalo. He was a post-doctoral fellowship at the Dupont-Merck Pharmaceutical, Co., a Research Scientist at Wyeth-Lederle Vaccines & Pediatrics and a Senior Research Scientist at North American Vaccines/Baxter Biosciences. In industry, he performed research in support of development of three approved vaccines, PREVNAR, Certiva, and NeisVac-C. As a Scientific Review Officer at NIAID he was responsible for organizing and leading large and complex review meetings of grants and contracts for construction of BSL-3/4 biocontainment facilities, development of bioinformatics resources for priority pathogens, testing of vaccine candidates, and pre-clinical testing resources for therapeutics resulting in over $1B in federal grant and contract awards. As a Therapeutics Program Officer at NIAID he negotiated and managed complex programs with pharmaceutical companies to perform preclinical/clinical product development of novel therapeutics to treat infectious diseases. He has negotiated and personally managed $250M of federal funding and provided support in negotiation and management of an additional $150M of federal funding. One program that he managed resulted in FDA approval of ANTHIM (obiltoxaximab) to treat and prevent inhalational anthrax and another anti-toxin program in advanced development for a broad spectrum multi-valent monoclonal antibody therapeutics to prevent and treat exposure to botulinum neurotoxins. John has advised NIAID’s Scientific Resources Development Team on developing a formal scientific management training program and assisted with Technology Transfer and Intellectual Property Office working with NIAID intramural investigators to foster technology development with other agencies and research organizations, and patenting and licensing of their inventions. He served as representative for NIAID in outreach to product development companies and service providers and has met with several hundred organizations to assess their capabilities.